Evidence map›Paper›PMID 42873420›Full record

ReviewInfectious diseases and therapy2026

Identification and Characterization of Patient Populations at High Risk for Clostridioides difficile Infection (CDI): A Narrative Review.

Jessica R Allegretti, Erik R Dubberke, Cátia Ferreira, Christian John Lillis, Mark H Wilcox

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jessica R AllegrettiDivision of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1175-1024
Erik R DubberkeDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-3779-2796
Cátia FerreiraBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA. catia.s.ferreira@icloud.com.
Christian John LillisPeggy Lillis Foundation, Brooklyn, NY, USA.ORCID http://orcid.org/0000-0003-3013-3843
Mark H WilcoxLeeds Institute of Medical Research, Leeds Teaching Hospitals, University of Leeds, Leeds, UK.ORCID http://orcid.org/0000-0002-4565-2868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridioides difficile infection (CDI) is a major cause of infections worldwide and can lead to life-threatening complications and a severe impact on patients' quality of life (QoL). CDI can affect anyone, but it is generally accepted that those at greatest risk include people receiving antibiotics, of older age, and with a compromised immune system. However, beyond these broad categories, specific populations at high risk for CDI are not clearly defined. We performed a literature search to identify and characterize patients at high risk for CDI. We found that those at high risk for CDI include patients undergoing hematopoietic stem cell transplant, solid organ transplant or chimeric antigen receptor T-cell therapy, or with chronic kidney disease/end-stage kidney disease, hematological malignancies or inflammatory bowel disease, or who are older and frail with comorbidities. In the identified patient populations, CDI was associated with significantly worse clinical outcomes, increased healthcare resource utilization and costs, and generally an increased risk of mortality compared with those without CDI. Patients at high risk for CDI have multiple risk factors for infection that further complicate management of their disease. Apart from older patients, there is a lack of information on the impact on QoL in high-risk populations. Prevention strategies for CDI in high-risk populations are lacking and are based on the general population. As such, there is a need to increase understanding of those at high risk for CDI and the significant impact infection has in these populations, and to identify preventive therapies to alleviate the burden on both patients and healthcare systems.

Indexed as

Burden of diseaseCDIClostridioides difficileClostridioides difficile infectionHigh-risk populationsUnmet need

Identifiers

PMID42873420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.